LLY

996.15

+1.15%↑

JNJ

243.81

+1.2%↑

ABBV

226.52

+0.7%↑

NVS

155.35

+0.92%↑

AZN

192.51

+0.34%↑

LLY

996.15

+1.15%↑

JNJ

243.81

+1.2%↑

ABBV

226.52

+0.7%↑

NVS

155.35

+0.92%↑

AZN

192.51

+0.34%↑

LLY

996.15

+1.15%↑

JNJ

243.81

+1.2%↑

ABBV

226.52

+0.7%↑

NVS

155.35

+0.92%↑

AZN

192.51

+0.34%↑

LLY

996.15

+1.15%↑

JNJ

243.81

+1.2%↑

ABBV

226.52

+0.7%↑

NVS

155.35

+0.92%↑

AZN

192.51

+0.34%↑

LLY

996.15

+1.15%↑

JNJ

243.81

+1.2%↑

ABBV

226.52

+0.7%↑

NVS

155.35

+0.92%↑

AZN

192.51

+0.34%↑

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Suletud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

50%

153 / 351 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. märts 2026, 23:12 UTC

Kuumad aktsiad

Stocks to Watch: Adobe, Mission Produce, Buzzfeed, Ulta

12. märts 2026, 22:15 UTC

Tulu

Wheaton Precious Metals Logs Higher 4Q Net Income, Boosts Dividend 18%

12. märts 2026, 21:42 UTC

Uudisväärsed sündmused

Stryker Says Cyberattack Disruption Is Continuing

12. märts 2026, 21:29 UTC

Uudisväärsed sündmused

Correction to War in Iran May Upend Brazil Central Bank's Plans Article

12. märts 2026, 21:27 UTC

Tulu

Adobe CEO to Depart as AI Boosts Sales -- Update

12. märts 2026, 20:46 UTC

Tulu

Adobe Posts Higher Sales With CEO Set to Depart

12. märts 2026, 20:21 UTC

Uudisväärsed sündmused

Soybean Futures Higher on Instability in Iran --Daily Grain Highlights

12. märts 2026, 23:57 UTC

Market Talk

Gold Edges Higher Amid Ongoing Middle East Conflict -- Market Talk

12. märts 2026, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12. märts 2026, 23:38 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

12. märts 2026, 22:13 UTC

Tulu

Orient Overseas: Tariff Measures, Trade Tensions Weighed on Results >0316.HK

12. märts 2026, 22:13 UTC

Tulu

Orient Overseas: Middle East Situation Have Added to Future Uncertainity >0316.HK

12. märts 2026, 22:13 UTC

Tulu

Orient Overseas: Charter Market Remains Exceptionally Tight With Vessels in Short Supply >0316.HK

12. märts 2026, 22:13 UTC

Tulu

Orient Overseas 2025 Rev $9.72B Vs. $10.70B >0316.HK

12. märts 2026, 22:13 UTC

Tulu

Orient Overseas 2025 Net $1.51B Vs. Net $2.58 >0316.HK

12. märts 2026, 22:13 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

12. märts 2026, 22:13 UTC

Market Talk

Tulu

Adobe Says Customers Want to Try AI Products for Free First -- Market Talk

12. märts 2026, 21:16 UTC

Omandamised, ülevõtmised, äriostud

Alexander & Baldwin: JV Formed by Affil of MW Group and Funds Affiliated With Blackstone and DivcoWest Completed Acquisition of All Outstanding A&B Common Shrs >ALEX

12. märts 2026, 21:04 UTC

Tulu

Adobe Earnings Beat Is Overshadowed by CEO Departure. The Stock Is Sliding. -- Barrons.com

12. märts 2026, 21:02 UTC

Tulu

Wheaton Precious Metals 4Q Adj EPS $1.22 >WPM

12. märts 2026, 21:02 UTC

Tulu

Wheaton Precious Metals 4Q Sales $865M >WPM

12. märts 2026, 21:02 UTC

Tulu

Wheaton Precious Metals 4Q Net $558.3M >WPM

12. märts 2026, 21:02 UTC

Tulu

Wheaton Precious Metals 4Q EPS $1.23 >WPM

12. märts 2026, 20:57 UTC

Market Talk

Uudisväärsed sündmused

No Need For Canada Rate Increases Amid Jump in Bond Yields -- Market Talk

12. märts 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

12. märts 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. märts 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

Eaton Completes Acquisition Of Leading Liquid-cooling Solutions Provider Boyd Thermal, Creating An Industry-leading Grid-to-chip Solution For Data Centers >ETN

12. märts 2026, 20:10 UTC

Tulu

Adobe Sees 2Q Rev $6.43B-$6.48B >ADBE

12. märts 2026, 20:05 UTC

Tulu

Adobe 1Q Rev $6.4B >ADBE

12. märts 2026, 20:05 UTC

Tulu

Adobe Sees 2Q Adj EPS $5.80-Adj EPS $5.85 >ADBE

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

153 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.